Meda Pharmaceuticals
Closed portfolio with a later-stage archive tilt
According to ClinicalTrials.gov-derived indexes, Meda Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#772 of 15,742 sponsors by registered trial count).
Meda Pharmaceuticals: 19 sponsored US clinical trials, none currently recruiting.
Meda Pharmaceuticals sponsors 19 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 19 completed. 19 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Seasonal Allergic Rhinitis, with 1 trials.
Top-decile sponsor footprint
Meda Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#772 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
19 of 19 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
19 total, page 1 of 1
Safety and Efficacy Trial of Dymista Nasal Spray in Children Ages 4 to 11 With Seasonal Allergic Rhinitis (SAR)
NCT01915823
Safety of Astepro 0.15% Nasal Spray and Astepro 0.1% Nasal Spray in Children Ages >6 Months to <6 Years With AR
NCT01880840
3 Month Safety Study of Dymista Nasal Spray and Fluticasone Propionate in Children 4-11 Years of Age With Allergic Rhinitis
NCT01794741
Open Label Safety Study of Xerese Cream in the Treatment of Recurrent Herpes Labialis in Children 6-11 Years Old
NCT01574612
A Study to Evaluate the Safety and Efficacy of a Nasal Spray to Treat Children With Perennial Allergic Rhinitis
NCT01018862
A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies
NCT00883168
A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies
NCT00824473
A Study Evaluating the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies
NCT00740792
Study to Evaluate Two Formulations of Carisoprodol in Subjects With Musculoskeletal Spasm of the Lower Back
NCT00671879
A Study to Evaluate Two Formulations of Carisoprodol in Subjects With Musculoskeletal Spasm of the Lower Back
NCT00671502
A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies
NCT00651118
A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies
NCT00660517
A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies
NCT00660829
A Study to Evaluate the Safety & Effectiveness of a Nasal Spray to Treat Seasonal Allergies
NCT00719862
A Study to Evaluate the Safety and Efficacy of Two Nasal Sprays to Treat Seasonal Allergies
NCT00720278
A Study to Evaluate the Safety and Tolerability of a Nasal Spray to Treat Perennial Allergic Rhinitis
NCT00720382
A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Perennial Allergies
NCT00712920
A Study to Evaluate the Safety and Efficacy of a Nasal Spray to Treat Seasonal Allergies
NCT01368445
Study to Evaluate the Safety and Tolerability of a Nasal Spray in Patients With Chronic Allergic or Nonallergic Rhinitis
NCT00783432
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 18 |
| Phase 4 | 1 |
Therapeutic Areas
How the Meda Pharmaceuticals archive is shaped
19 indexed studies, none listed as recruiting (0% open); 19 completed (100%).
Phase mix: 19 late (III/IV) vs 0 early (I/II) (later-stage heavy).
Top condition: Seasonal Allergic Rhinitis (1 trial), 2 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Meda Pharmaceuticals: archived-pipeline peers nationwide
Peers matched on 19 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Meda Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 19 archived trials
- Almirall, S.A. · 19 trials · 5% recruiting
- Bastyr University · 19 trials · 11% recruiting
- Church & Dwight Company · 19 trials · 0% recruiting
- Cordis US · 19 trials · 5% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Meda Pharmaceuticals page
19 registered trials is a research-attention snapshot, not an endorsement of Meda Pharmaceuticals or any single study.
- None of Meda Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Seasonal Allergic Rhinitis is the condition Meda Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Seasonal Allergic Rhinitis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Meda Pharmaceuticals pipeline card: 19 registered trials from official public datasets.Report a data error.